share_log

Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15

Benzinga ·  Dec 27, 2023 14:23

Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $16 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment